MGMT and neoplasm: However, when OS2 was compared separately (median OS 471.817 days versus 243.267 days), there was a significant difference in the unmethylated MGMT patients, who appeared to benefit from a former treatment with TMZ after tumor recurrence and upgrading to sGBM (p<0.001, Table 4, Figure 7B).